Source: Population Reseach
New Report on FDA Approval of ‘Emergency Contraception’
WASHINGTON, DC, 31 March 2004 — Population Research Institute has released an in-depth report on so-called “emergency contraception.”
The U.S. Food and Drug Administration (FDA) has delayed its decision to act on Women’s Capital Corporation/Barr Laboratories application for over-the-counter (OTC) status for so-called “emergency contraception”(EC), the morning-after pill (MAP).
Opposition to OTC/MAP involves concerns that OTC/MAP would increase rates of rape, STDs, abortion and sexual promiscuity among teenaged girls. Efforts in America to obtain OTC/MAP status are a final step in a coordinated campaign undertaken by international abortion advocacy/population control organizations.
The dangers of MAP were ignored at the December 2003 FDA advisory committee meeting on OTC/MAP. Risks include: ectopic pregnancy; long-term use; pregnancy-related risks; risks of misuse and overdose; increased rates of STD/HIV infection; increased rates of induced abortion; increased rates of sexual violence, and risks associated with interactions with other drugs. Post-marketing surveillance of OTC/MAP will not mitigate these risks.
Claims of widespread demand for OTC/MAP appear to have emerged almost overnight. For many years, however, global social marketing campaigns have been quietly laying this foundation. Ad campaigns include strategies to obfuscate its abortion-inducing nature, and make inroads into public school populations. Advertising themes, supported by both USAID and a host of international and domestic abortion groups, have ranged from promoting promiscuity to selling MAP as a solution to rape.
In 1995, Dr. Sharon Camp, founder of FDA OTC/MAP applicant Women’s Capital Corporation, convened global regional groups for MAP social marketing campaigns, pursuant to a consensus statement ratified by international abortion groups at a special conference in 1995 at Bellagio, Italy. The next year, an International Consortium at which USAID participated succeeded in securing the manufacture of MAP for social marketing worldwide. USAID-funded groups have promoted MAP, to girls as young as 10 years old, in nations where it is illegal to do so.
FDA approval for OTC/MAP status should be denied.
Population Research Intsitute is dedicated to ending human rights abuses committed in the name of family planning and through research to dispelling the mythe of overpopulation.
Source: Population Research Institute